Answers are grounded in this paper and cite their sources.
Purpose. Rapid weight loss with GLP-1 receptor agonists removes lean mass, and whether this weakens the pelvic floor and causes incontinence is under prospective study. We tested this mechanism against spontaneous reports. Methods. Disproportionality analysis of FAERS with validation in Canada Vigilance, using an active comparator set of diabetes and obesity drugs, adjusted reporting odds ratios (ROR), SGLT2 inhibitors as positive control, and tests of the competing pelvic floor and diabetic bladder hypotheses. Results. In FAERS and Canada Vigilance, GLP-1 receptor agonists as a class were not disproportionately reported with lower urinary tract events (adjusted ROR 0.43 and 0.50). Without SGLT2 inhibitors in the comparator set, semaglutide and DPP-4 inhibitors showed modest excess reporting of lower urinary tract events and urinary tract infection, tirzepatide did not. Semaglutide showed an incontinence signal in women (1.44, 95% CI 1.14 to 1.81; sex interaction p 0.02). It was numerically less frequent with obesity than diabetes use (OR 0.66, 0.34 to 1.28) and with Wegovy than Ozempic (0.64, 0.36 to 1.16), showed no dose-related increase among injectable reports, began early (median 2 days in 23 reports with dates), and clustered with urinary tract infection and other lower urinary tract symptoms, not with weight loss. Conclusion. The semaglutide incontinence signal was early in onset, more frequent in diabetes-indicated reports and embedded in a urological cluster. This pattern is more compatible with diabetes-related urinary morbidity than with pelvic floor weakening, although spontaneous reports cannot settle mechanism, and does not support withholding treatment for fear of incontinence.
No takes yet. Share an insight, caveat, or question.
Selimoğlu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: